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acquired diseases has opened a new era in human gene therapy.
However, variability in the efficacy and safety of this thera-
peutic approach has been reported in human patients. Conse-
quently, lentiviral-vector-based gene therapy is limited to
incurable human diseases, with little understanding of the un-
derlying causes of adverse effects and poor efficacy. To assess
the role that host genetic variation has on efficacy of gene ther-
apy, we characterized lentiviral-vector gene therapy within a
set of 12 collaborative cross mouse strains. Lentiviral vectors
carrying the firefly luciferase cDNA under the control of a
liver-specific promoter were administered to female mice,
with total-body and hepatic luciferase expression periodically
monitored through 41 weeks post-vector administration. Vec-
tor copy number per diploid genome in mouse liver and spleen
was determined at the end of this study. We identified major
strain-specific contributions to overall success of transduction,
vector biodistribution, maximum luciferase expression, and
the kinetics of luciferase expression throughout the study.
Our results highlight the importance of genetic variation on
gene-therapeutic efficacy; provide new models with which to
more rigorously assess gene therapy approaches; and suggest
that redesigning preclinical studies of gene-therapy methodol-
ogies might be appropriate.Received 8 February 2017; accepted 30 March 2017;
http://dx.doi.org/10.1016/j.omtm.2017.03.009.
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Similar to other viral vectors, lentiviral vectors are designed to support
a single round of transduction process1 comprising multiple steps,
which are dependent on unique host factors and can also be restricted
by retroviral-specific restriction factors as well as the host innate and
adoptive immune responses.2–8 The process of a single-round vector
transduction includes vector attachment to the relevant envelope
receptor on the host cell membrane, uncoating,9–13 reverse transcrip-
tion, nuclear import,14–16 integration,15,17,18 and transgene expres-
sion.19 Notwithstanding the central role of the host factors in the
process of viral infection, current preclinical studies, which determine
the efficacy and safety of viral vectors are usually based on rodentMolecular Therapy: Method
This is an open access article under the CC BY-Nstudies comprising a large cohort of genetically identical animals, fol-
lowed by a large animal (e.g., primate) study using a relatively small
number of outbred animals. Consequently, several clinical trials using
various viral vectors resulted inmajor adverse effects that could not be
predicted by their cognate preclinical studies.20–24 Furthermore, the
limited numbers of individuals who are eligible for gene therapy clin-
ical trials and the fact that these individuals already have significant
health issues limit our ability to meaningfully use their outcome to
determine what were the host genetic variants that put these individ-
uals at higher risk for adverse effects or rendered them likely to benefit
from gene therapy protocols. Advancements in the lentiviral vector
system were followed by successful human clinical trials on either
gene replacement or immunotherapy for either fatal monogenic dis-
eases or cancer, respectively.20,25–30 Notwithstanding the overall suc-
cesses of the above clinical trials, significant variation was observed
in the efficacy and safety both between the trials as well as within
patients in a specific trial. Notably, among all HIV-1 vector-treated
patients, only one patient who received hematopoietic-stem-cell-
directed gene replacement therapy of b-thalassemia demonstrated
vector-induced insertional mutagenesis.20 The variability in the effi-
cacy and safety of HIV-based vector clinical trials was in line with
earlier preclinical studies, which demonstrated significant strain-spe-
cific differences in HIV-1 vector efficacy and safety.31,32 However, the
low numbers of animal and inbred strains employed in these studies
limited the ability to assess the impact of specific genetic differences
on these phenomena. Indeed, given the growing body of evidence
that host genetic variants can impact antiviral responses33–35 as well
as overall gene regulation within individuals,36–38 being able to accu-
rately assess and quantify genetic variants effects on gene therapy
approaches is critical for the advancement of this field.s & Clinical Development Vol. 5 June 2017 ª 2017 The Author(s). 83
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. In Vivo Luciferase Expression across Mouse Strains
Following introduction of a luciferase-expressing lentivirus, female mice from several strains were followed over 41 weeks, with regular assessment (weeks 1, 3, 7, 15, and 41
post-lentiviral vector administration) of in vivo luciferase expression (p/s/cm2/sr); color scale set between 5 104 and 1 106. Here, the standard laboratory strain C57BL/6J
is compared to the highly expressing CC061/GeniUnc strain as well as the low/non-expressing CC013/GeniUnc and CC024/GeniUnc strains.
Molecular Therapy: Methods & Clinical DevelopmentRelevant for studies of in vivo mammalian responses, the collabora-
tive cross (CC) panel of recombinant inbred mouse strains exists.39
This genetic reference panel of >70 inbred mouse strains were derived
from a set of eight founder strains, including five classical laboratory
mouse strains, and three wild-derived strains. Together, these foun-
ders represent all three Mus musculus subspecies and contain over
40 million SNPs and four million insertions and deletions segregating
at high minor allele frequencies across the collaborative cross.
Furthermore, across a growing number of studies, variants within
the collaborative cross and related diversity outbred (DO) have
been shown to impact a variety of antiviral40–44 and gene-regulatory
processes.36,45 Specifically, a number of these studies have identified
host genetic variants impacting innate antiviral responses40,42 and
also aberrant adaptive immune responses to pathogens.41 Given the
reliance of gene therapeutic efficacy assessments on one or two classic
inbred strains (e.g., C57BL/6 or BALB/c), diverse populations such as
the collaborative cross provide a useful tool with which to assess the
impact of host genetic variation on the potential efficacy of vector-
based gene therapeutic approaches and potential off-target effects
and ultimately to identify polymorphic genome features driving these
responses. In order to assess the impact of host genetic variation on
the efficacy as well as safety of a lentivirus-based gene therapeutic
regimen, we transduced 12 collaborative cross strains as well as
C57BL/6J mice with a liver-targeting lentivirus vector expressing
luciferase. We found evidence of strong effects of host genetic variants
on the ability of the lentiviral vectors to successfully ferry genetic84 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017cargos to host cell nuclei and maintain hepatic transgene expression.
This study highlights the critical need to assess the safety and efficacy
of gene therapeutic approaches across a range of genetically variable
backgrounds.
RESULTS
Host Genetic Variation Controls Both Levels and Kinetics of
Luciferase Expression
To evaluate the effects of host genetic variation on lentiviral-vector-
based gene delivery in vivo, we administered lentiviral vectors via
intraperitoneal injection to 64 female mice from 12 collaborative
cross strains as well as to the prototypical model C57BL/6J (n = 4
to 5/strain). These collaborative cross strains were chosen based on
the availability of sufficient sized cohorts within our age window at
the time of this study and were also selected to sufficiently and unbias-
edly sample the genetic variation present within the entire collabora-
tive cross population (e.g., these strains did not represent a genetically
biased subset of strains). One mouse died during injection, and two
other mice were excluded from the study because of post hoc obser-
vation of failure to deliver the vector to these animals. The vectors
were VSV-G pseudotyped and expressed firefly luciferase under the
control of a liver-specific promoter (human alpha1-antitrypsin
[hAAT]). Luciferase expression in liver and whole mouse body was
quantified by in vivo imaging at weeks 1, 3, 7, 15, and 41 (Figures 1
and S1). At 1 week post-infection, we identified an almost 2-log dif-
ference between mouse strains in their total-body luciferase (Log10
Figure 2. Time Course of Luciferase Responses across Mouse Strains
(A–C) Whole body (A), liver-specific (B), and off-liver luciferase activity was calculated by subtracting liver-specific activity from whole-body luciferase activity (C). Log10
luciferase levels (photon/s) were assessed for each animal across a 41-week time course. (D) We also assessed the percentage of luciferase signal coming from the liver of
each mouse at each time point. Figures show mean and SD of each strain at each time point measured for the appropriate trait. Time points are color coded as indicated.
www.moleculartherapy.orgrange of 5.78–7.27 photons/s). The classic C57BL/6J strain was inter-
mediate in its luciferase levels (Log10 mean [SD] = 6.41 [0.58]) at
this time point relative to the collaborative cross strains (Figure 2;
Table 1). Differences between collaborative cross strains in total lucif-
erase expression were highly significant (F11,44 = 9.64; p < 1  105).
In order to better ascertain the percentage of phenotypic variation in
this population, which can be attributed to genetic differences be-
tween strains, we estimated the broad-sense heritability46 (for more
details, see Materials and Methods) to be between 46% and 63%
(the more conservative coefficient of genetic determination [cgd]
was 0.463, whereas the more liberal interclass correlation [icc] was
0.633). Looking across this time course, we identified significant
effects of strain (F11,234 = 30.08; p < 1  1010), time (F1,234 =
3.979; p = 0.047), as well as the interaction between these two factors
(F11,234 = 2.9161; p = 0.001) on whole-body luciferase expression
through this study. These responses can be seen clearly in Figure 2
and Table 1. Overall, modest increases in luciferase expression were
seen through the experiment. However, some strains (e.g., CC008/
GeniUnc and CC024/GeniUnc) showed stable luciferase expression
throughout the experiment, and one strain (CC021/Unc) showed
reduced luciferase expression throughout the study. Ideally, gene
therapeutic products are specifically targeted to a given tissue. We
were able to assess the liver-specific expression of luciferase across
our set of mouse strains through this kinetic time course. In general,
total and liver-specific luciferase levels were highly correlated (r2 =
0.96, Figure 3A) throughout the study, and, therefore, analysis of
these data tightly mirrored the responses seen for total luciferase
levels. In liver, we found evidence of strain effects (F11,234 = 40.157;
p < 1  1010), and also a strain-by-time point interaction
(F11,234 = 3.18; p < 0.001). However, although we identified a moder-
ate effect of time point on total luciferase levels, we did not identify
an effect of time point (F1,234 = 0.0012; p = 0.97) on liver-specificMolluciferase expression. Furthermore, at week 1, we found that as
with total luciferase, liver-specific luciferase expression heritability
was high, ranging from 46% to 64% (cgd = 0.466; icc = 0.636). Exam-
ination of these data (Table 2) shows that in general, liver-specific
levels were stable through the study, with some strains showing
modest changes in effect. Given these lines of evidence, especially
the discordance between the temporal responses for total and liver-
specific luciferase, we finally asked whether the overall proportion
of luciferase expression within individuals was under host genetic
control. We first examined the correlation between total luciferase
expression and the fraction of luciferase signal coming from the liver
and found a modest correlation between these two traits (r2 = 0.579,
Figure 3B). Importantly, samples having a broad range of total lucif-
erase expression (105–107.3 photons/s) could still exhibit low levels
(20%) of liver-specific expression, suggesting that those individual
animals with low fractions of liver-specific responses were not just
those with low total levels (e.g., samples difficult to assess or incorrect
attribution to spillover from the liver). Therefore, we assessed how
this response changed throughout the study. As we expected, we iden-
tified significant strain (F11,234 = 56.3; p < 1  1010), time point
(F1,234 = 27.9; p < 1 106), and an interaction between these factors
(F11,234 = 2.14; p = 0.018) driving the fraction of luciferase expression
coming from liver, with heritability estimates at week 1 ranging from
49% to 66% (cgd = 0.493; icc = 0.66). For example, CC033/GeniUnc
and CC061/GeniUnc both maintain consistently high proportions of
their total luciferase coming from liver similar to C57BL/6J, whereas
CC013/GeniUnc showed a decreasing fraction of expression coming
from the liver over time. Note that only C57BL/6J and CC035 showed
increases in the fraction of their response coming from the liver, sug-
gesting that although there might be fluctuations between tissues or a
silencing within the liver, in most strains, there was no expansion of
the luciferase expression from this tissue.ecular Therapy: Methods & Clinical Development Vol. 5 June 2017 85
Table 1. Mean ± SD of Log10 Total Luciferase Activity Levels Measured in
Photons/s through Time Course
Mouse Strain Week 1 Week 3 Week 7 Week 15 Week 41
C57BL/6J 6.41 (0.58) 6.88 (0.47) 6.86 (0.41) 7.01 (0.40) 7.36 (0.37)
CC008/GeniUnc 6.58 (0.97) 6.38 (0.73) 7.04 (0.17) 7.04 (0.21) 6.58 (0.48)
CC013/GeniUnc 5.94 (0.13) 5.89 (0.16) 6.00 (0.27) 6.21 (0.12) 5.97 (0.62)
CC016/GeniUnc 7.19 (0.31) 6.96 (0.31) 7.56 (0.33) 7.52 (0.28) 7.70 (0.25)
CC021/Unc 7.09 (0.60) 6.53 (0.58) 6.38 (0.51) 6.35 (0.82) 5.76 (NA)a
CC024/GeniUnc 6.75 (0.19) 6.69 (0.26) 6.77 (0.26) 6.91 (0.12) 6.63 (0.52)
CC028/GeniUnc 6.35 (0.43) 6.40 (0.23) 6.87 (0.38) 6.81 (0.31) 6.84 (0.55)
CC030/GeniUnc 6.36 (0.08) 5.97 (0.18) 6.41 (0.51) 6.59 (0.14) 6.22 (0.49)
CC033/GeniUnc 6.37 (0.37) 6.69 (0.11) 7.34 (0.42) 7.29 (0.39) 7.12 (0.44)
CC035/Unc 5.78 (0.11) 6.33 (0.18) 6.44 (0.21) 6.49 (0.15) 6.81 (0.29)
CC056/GeniUnc 7.27 (0.33) 7.22 (0.35) 7.12 (0.29) 7.00 (0.29) 7.07 (0.32)
CC061/GeniUnc 7.44 (0.33) 7.90 (0.35) 8.08 (0.18) 7.66 (1.04) 7.27 (0.87)
CC065/Unc 5.82 (0.22) 5.63 (0.51) 6.14 (0.35) 6.18 (0.36) 6.39 (0.58)
aOnly one animal survived to this time point.
Molecular Therapy: Methods & Clinical DevelopmentDifferential Success in Stable Vector Maintenance
Following reverse transcription, lentiviral vectors efficiently import
their genetic material to the host cells’ nuclei, where it serves as a tem-
plate for transcription of the relevant transgene of interest. Successful
gene therapy with these vectors requires long-term persistence of
vector-transduced cells. Following study termination, liver and spleen
tissues were collected from these animals, and a qPCR assay was per-
formed to identify the number of vector copies delivered into host
cells’ nuclei. Vector copy number per cell (VCN) in the liver differed
by over 2 logs (min = 0.001; max = 1.12; mean = 0.22 copies/cell;
Figure 4A). C57BL/6J showed the highest level of VCN within the
livers (0.85 ± 0.22 copies/cell), with all collaborative cross strains
showing lower levels of VCN than C57BL/6J. Collaborative cross
strains showed significant differences in liver VCN (F11,31 = 8.023;
p = 2.1  106), and heritability estimates suggest that between
41% and 58% (cgd = 0.412; icc = 0.584) of the variation in vector
copies/cell in the liver are under host genetic control. Levels of
VCN within the spleen of most strains were reduced relative to liver
(min < 0.001; max = 0.33; mean = 0.09 copies/cell), although there
was a strong correlation between vector copies in the liver and vector
copies in the spleen (r2 = 0.78). C57BL/6J showed relatively high levels
of vector copies/spleen (0.13 ± 0.08 vector copies per cell), but in
contrast to liver-specific VCN, C57BL/6J was not the mouse strain
with the highest levels of spleen VCN (Figure 4B). As with liver levels,
there was an approximately 1.5-log difference between the highest
and lowest collaborative cross strain, and these differences were sta-
tistically significant (F11,29 = 4.247; p = 0.0008). Spleen levels of vector
maintenance had a heritability of between 25% and 39% (cgd = 0.245;
icc = 0.393) across these collaborative cross strains.
Relationship between VCN and Luciferase Expression
Given the highly significant variation in total and liver-specific lucif-
erase expression between this collection of mouse strains, we sought86 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017to assess the extent to which host genetic differences controlled these
expression levels (that is, given the strain-specific VCN, are there dif-
ferences in the efficiency of transgene expression). We determined the
relative expression of luciferase at week 41 within the livers of each
mouse relative to liver VCN. We found that vector-specific activity
in mouse livers (F11,28 = 2.81; p = 0.013) was impacted by the host
strain (Figure 4C). Heritability analysis showed that between 15%
and 27% (cgd = 0.153; icc = 0.266) of the variation in vector-specific
activity in the liver was explained by host genetic variation. We uti-
lized a second analysis to assess the impact of host genetic variation
on luciferase expression independent of host genetic variations’
impact on vector copy number. We used a partial F-test to assess
the improvement in fit when our model explaining luciferase levels
included both strain and vector copy number as opposed to vector
copy number alone. We found strong evidence for liver luciferase
expression having other host factors driving expression (F27,38 =
3.26; p = 0.005), although the evidence for total luciferase expression
was not significant (F26,36 = 1.78; p = 0.11).
Mortality and Atypical Pathological Responses across This
Treated Cohort
A total of 12/61 (19%) mice within this study died during the course
of this experiment. This mortality impacted seven strains (Table S1),
with CC021/Unc experiencing the highest mortality (4/5 mice). After
sacrifice, six mice from four strains showed what appeared to be a
macroscopic abnormality, including liver (CC024/GeniUnc#1) and
spleen (CC035/Unc#5) tumors. Pathological analysis suggested these
were common lesion types in aging animals and unlikely to be due to
the presence of vector-related issues (Figure S2; Table S2).
DISCUSSION
Although gene therapy approaches have the power to alleviate se-
vere congenital conditions, several aspects of viral-vector-delivered
gene therapeutic regimens have raised causes for concern. Specif-
ically, successful gene therapy requires optimal responses to a vari-
ety of processes, all with a single delivery event. These include, but
are not limited to, delivery of viral vectors to specific target cells,
efficient transfer of viral genomes to host cells’ nuclei, and mainte-
nance of therapeutic levels of transgene expression without causing
harmful adverse effects. Inefficiency in these processes as well as
unforeseen adverse effects in some clinical trials have been the great-
est impediments to broad adoption of gene therapy as a means to
treat nonfatal diseases.20,22–24 Although some studies have suggested
that host genetic differences can play a role in gene therapy out-
comes,31,32 there has been little research into the role that host
genetic variation plays on the efficacy, maintenance, and safety of
viral-vector-driven gene therapeutic approaches. We sought to
assess the magnitude of the impact that host genetic variation could
have on gene therapeutic efficacy. We used a set of strains from the
collaborative cross genetic reference panel, and found that host
genetic variation impacted multiple aspects of the gene therapy
response within hosts, and, furthermore, that these responses were
not always correlated across the strains (e.g., VCN and total lucif-
erase expression).
Figure 3. Relationships between Luciferase
Expression Levels
(A) A strong correlation (r2 = 0.96) was identified across all
time points between the liver-specific and total-body levels
of luciferase expression. (B) A moderate (r2 = 0.57) corre-
lation was identified between total luciferase levels and the
percentage of luciferase signal coming from the liver. Each
point is from a single mouse at a single time point, with
C57BL/6J shown as red points and collaborative cross
mice shown as blue points.
www.moleculartherapy.orgC57BL/6J is one of the most widely used mouse strains and is in fact
the reference mouse genome. Various mouse models emulating hu-
man diseases were established on a C57BL/6J genetic background.
These include several lines of C57BL/6J-factor-IX-deficient mice,
which modeled hemophilia.47–50 Using adenoviral- and AAV-based
vectors in gene therapy preclinical studies of hemophilia B, Fields
et al. and Mingozzi et al. demonstrated that induction of immune
tolerance to and long-term therapeutic levels of expression of vec-
tor-delivered human factor IX were more readily achieved in
C57BL/6 mice compared to BALB/c, C3H, and CD-1, although pre-
cise assessment of the genetic contributions within these studies
was not characterized.51,52 In an earlier lentiviral-vector-based pre-
clinical study, Follenzi et al. showed superior lentiviral vector long-
term expression of and less prominent adaptive immune response
to vector-delivered GFP reporter gene and human factor IX in
C57BL/6 mice compared to FVB/N and BALB/c mice. Not surpris-
ingly, C57BL/6 mice are considered the most permissive model for
lentiviral-vector-based gene delivery.31 In line with the Follenzi studyMolecular Therapy: Methoabove, we found that peak luciferase expression
in the C57BL/6J strain was higher (>1  107.36)
than in many collaborative cross strains in this
study. Importantly, in this study, two collabora-
tive cross strains (CC016/GeniUnc and CC061/
GeniUnc) exhibited equivalent or higher levels
of transgene expression than the C57BL/6J strain
at later time points. Furthermore, our study
showed differences in peak luciferase expression
across strains as >100-fold. These data suggest
that significant differences in the efficacy of
gene therapy protocols between human pa-
tients can be anticipated solely due to genetic
differences.
In addition to peak levels of transgene expres-
sion, long-term maintenance of therapeutic
levels of vector-delivered transgenes is a required
characteristic of in vivo gene transfer procedures
and directly affects the success of in vivo gene
therapy protocols. An early study by Zhang
et al. associated the development of humoral im-
mune response to human factor IX delivered by
AAV-based vectors with slow kinetics of in vivotransduction.53 In our study, the kinetics of lentiviral-vector-medi-
ated luciferase expression throughout the study differed significantly
between mouse strains. Although there were modest increases in
luciferase expression inmost strains, a subset of strains showed reduc-
tion of luciferase expression throughout the study. Most notably, this
was seen in the strain CC021/Unc, which showed decreasing levels of
luciferase expression throughout the study and also showed high
mortality throughout the study. Overall, these results were in line
with earlier studies showing stable long-term expression of luciferase
and human factor IX from integrating lentiviral vectors in immune-
competent C57BL/6J mice.54,55 However, other earlier lentiviral-
vector-based preclinical studies reported on dramatic reduction in
transgene expression between weeks 2 and 4 post-injection.31,56
This phenomenon was alleviated in a transgene-dependent manner
by inhibiting off-target transgene expression in antigen presenting
cells.56–58 Several mechanisms can contribute to reduction in vec-
tor-delivered transgene expression and thus limit the efficacy and
safety of gene therapy protocols. These mechanisms include adaptiveds & Clinical Development Vol. 5 June 2017 87
Table 2. Mean ± SD of Log10 Liver-Specific Luciferase Activity Levels
Measured in Photons/s through Time Course
Mouse Strain Week 1 Week 3 Week 7 Week 15 Week 41
C57BL/6J 6.30 (0.66) 6.82 (0.51) 6.74 (0.52) 6.92 (0.45) 7.24 (0.43)
CC008/GeniUnc 6.28 (1.23) 5.99 (0.94) 6.65 (0.19) 6.45 (0.27) 5.77 (0.44)
CC013/GeniUnc 5.68 (0.12) 5.58 (0.15) 5.53 (0.25) 5.75 (0.12) 5.29 (0.58)
CC016/GeniUnc 7.14 (0.35) 6.91 (0.31) 7.50 (0.33) 7.45 (0.29) 7.61 (0.29)
CC021/Unc 6.97 (0.67) 6.42 (0.65) 6.26 (0.55) 6.17 (1.02) 5.76 (NA)a
CC024/GeniUnc 6.35 (0.32) 6.17 (0.43) 6.13 (0.51) 5.94 (0.50) 5.82 (0.66)
CC028/GeniUnc 6.14 (0.47) 6.13 (0.26) 6.59 (0.47) 6.55 (0.47) 6.56 (0.65)
CC030/GeniUnc 6.05 (0.13) 5.59 (0.18) 6.04 (0.57) 6.20 (0.18) 5.92 (0.59)
CC033/GeniUnc 6.31 (0.38) 6.66 (0.11) 7.29 (0.47) 7.23 (0.43) 7.02 (0.48)
CC035/Unc 5.55 (0.18) 6.16 (0.24) 6.16 (0.26) 6.26 (0.23) 6.62 (0.32)
CC056/GeniUnc 7.22 (0.35) 7.08 (0.50) 6.92 (0.50) 6.73 (0.32) 6.87 (0.34)
CC061/GeniUnc 7.39 (0.34) 7.86 (0.36) 8.04 (0.18) 7.58 (1.10) 7.17 (0.92)
CC065/Unc 5.34 (0.20) 5.15 (0.58) 5.53 (0.40) 5.56 (0.38) 5.64 (0.44)
aOnly one animal survived to this time point.
Molecular Therapy: Methods & Clinical Developmentimmune response directed to vector-transduced cells, adaptive
immune responses to the vector-delivered gene products them-
selves,23,31,56,59,60 transgene toxicity, and silencing of the vector
expression cassette.61 Previous clinical trials and other studies have
suggested that immune responses against targeted cells can lead
to adverse effects.23,24,60,62 Although our study was not able to conclu-
sively investigate whether this transgene silencing and mortality were
connected and if they were the results of immune responses, these
data suggest that there are host genotype-specific responses that
can lead to suboptimal and adverse gene therapeutic responses.
Vector biodistribution is a key characteristic of all gene-delivery sys-
tems. Lentiviral vector biodistribution is controlled by the efficiency
at which reverse-transcribed vector genomes are nuclear imported
and expressed in various host organs following systemic administra-
tion. The ability of HIV-1 to transduce non-dividing cells, which
facilitates in vivo gene delivery, is the hallmark of lentiviruses and
lentiviral vector systems.63,64 Surprisingly, to date, the effects of
host genetic variation on vector biodistribution has not been char-
acterized. We were able to identify a difference in the success of
VSV-G-pseudotyped lentiviral vectors to deliver reverse-transcribed
genomes into both desired target (liver) and bystander (spleen) tis-
sues (expressed as VCN) between the collaborative cross strains we
assessed. With the exception of three mouse strains (C57BL/6J,
CC056/GeniUnc, and CC061/GeniUnc), in which VCN levels in liver
tissues were remarkably high, all other collaborative cross mouse
strains exhibited comparable levels of VCNs in liver and spleen tis-
sues. Furthermore, there was a strong correlation across all animals
in the level of copies between tissues. These findings are in line
with an earlier report by Pan et al. showing comparable VCN levels
in liver and spleen tissues following intravenous administration of
VSV-G-pseudotyped lentiviral vectors to BALB/c mice.65 These re-
sults suggest there are some variant host factors, which impact the88 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017efficacy of delivery or maintenance of cells transformed by the vector.
Nuclear import of vector DNA is a prerequisite for vector transcrip-
tional activity and directly affects biodistribution of transgene expres-
sion. However, vector design and host factors also have major effects
on transgene expression in vector-transduced cells. In this study, a
liver-specific promoter (hAAT) controlled vector-mediated luciferase
expression. Indeed, most mouse strains exhibited predominantly
hepatic expression. However, several mouse strains demonstrated
relatively high extra-hepatic transgene expression. Furthermore,
an earlier study reported on extra-hepatic transgene expression
in non-hepatic cell lines in vitro and extra hepatic tissues in vivo
and from lentiviral vectors carrying a liver-specific promoter.59
Although the mechanism involved in this phenomenon has not
been completely elucidated, it was generally attributed to enhancer/
promoter effects of the host chromatin on liver-specific promoters
in integrated lentiviral vectors.56,66 In addition to VCN levels, specific
activity of a lentiviral vector expression cassette as determined by total
transgene activity per vector genome directly affects the therapeutic
efficacy of a lentiviral vector as a therapeutic agent. Although vec-
tor-specific activity was comparable across the collaborative cross
mouse strains, significant high specific activity was exhibited by strain
CC016/GeniUnc. Furthermore, and strikingly, both the prototypical
C57BL/6J and CC061/GeniUnc strains showed much more modest
specific activity than their overall luciferase expression levels would
indicate, further highlighting the need for assessment of both trans-
duction efficiency as well as transgene expression in considering
the success of gene therapy. This phenomenon can be attributed to
a single or a combination of strain-specific transcriptional and
post-translational host factors, which enhanced luciferase activity in
the above mouse strain. This observation is highly important in the
gene therapy field because it strongly suggests that therapeutic vector
loads should be patient specific. This approach could potentially
reduce transgene cytotoxicity on one hand and optimize overall vec-
tor genomes required to achieve therapeutic transgene expression
with minimal adverse effects on the other hand. Indeed, insertional
mutagenesis is a major biosafety inherent to all integrating vectors,
including lentiviral vectors. A previous study found some evidence
for differential oncogenic potential.32 We identified mice from four
of the 12 collaborative cross strains used in this study (Table S2),
which had macroscopic liver abnormalities following termination.
The presence of these abnormalities did not appear to be tied to the
lentiviral transduction, and the propensity to develop specific cancer
types is known to be under genetic control.67,68 However, more in-
depth future studies in a more robust case-control framework will
be required to both understand any potential exacerbation of tumor-
igenesis driven by lentiviral vectors as well as to assess the distribution
of integration into oncogenes and the extent to which host genetic
differences directly (e.g., integration site biases) or indirectly (e.g.,
epigenetic and chromatin differences) might alter this. Here, we
have demonstrated the strong effects of host genetic variation on
the levels and kinetics of transgene expression, levels of VCN, and
vector-specific activity. A larger number of collaborative cross strains
should facilitate identification of putative genetic loci involved in the
above strain-specific characteristics of in vivo lentiviral vector gene
Figure 4. Vector Copy Number and Luciferase Levels per Vector Copy Vary between Strains
(A and B) We assessed vector copies at study conclusion and found significant strain-specific differences in levels of vector copy number in liver (A) and spleen (B) at these
time points. (C) We also determined luciferase levels per vector copy in liver tissues (Log10 (liver-specific luciferase/liver VCN)) based on week 41 luciferase levels and found
strain-specific levels of specific activity. Each point is one animal, with C57BL/6J mice in red and collaborative cross strains in blue.
www.moleculartherapy.orgdelivery. To avoid gender-specific effects on hepatic transduction,
this study was premised on female mice only. Although more
resource demanding, additional studies comprising male mice are
needed to identify gender-specific effects on lentiviral vector trans-
duction efficiency.
We anticipate that using the collaborative cross mouse system in an
in vitro setting would further elucidate the molecular mechanisms
by which host genetic variation affects specific steps in the HIV-1
life cycle. However, establishing the ability to genetically identify
host factors affecting the efficacy of lentiviral vectors ferrying thera-
peutic genetic cargos in the setting of a genetic disease model will
be more challenging.
MATERIALS AND METHODS
Lentiviral Particles Production, Concentration, and Titration
Lentiviral vector (pTK979) harboring the firefly luciferase cDNA
under the control of a liver-specific promoter (hAAT) was con-
structed and used as described earlier.54 Lentiviral vector particles
were packaged with the packaging cassette,DNRF, in 293T cells using
three-plasmid transient transfection as previously described.69 Vector
titer was determined by measuring the p24 capsid concentration us-
ing ELISA as previously described.70 All vector preps were tested for
the absence of replication-competent retrovirus as described earlier.71
Animal Studies
All procedures involving animal study were performed in accordance
with theGuide for theCare andUse of LaboratoryAnimals. The animal
study protocol was approved by the University of North Carolina
(UNC) Institutional Animal Care and Usage Committee. All mice
were purchased from JacksonLaboratories (C57BL/6J) or theUNCSys-
temsGenetics Core Facility (collaborative cross strains listed in Table 1;
http://csbio.unc.edu/CCstatus/index.py?run=AvailableLines). Female
mice were acquired at 5 to 6 weeks of age, and acclimated for 1 week
in our experimental facility. Female animals (n = 4 to 5/strain) were
intraperitoneally injected with 50 mg of p24gag lentiviral vectors
(in 250 mL of phosphate-buffered solution). In vivo expression of vec-
tor-delivered firefly luciferase in live animals was determined at weeks
1, 3, 7, 15, and 41 using the IVIS Lumina optical imaging systemMol(PerkinElmer). To this end, animals were intraperitoneally injected
with 200 mL (5mg) of D-luciferin potassium salt reconstituted in phos-
phate-buffered solution (Regis Technologies). Imaging was initiated
10 min after D-luciferin injection using a 5-min exposure time. The
relative light counts obtained through a charge-coupled device (CCD)
camera were converted to physical units of surface radiance (p/s/
cm2/sr) and displayed in luminescence radiancemode. All in vivo lucif-
erase activities shown in this study were analyzed using Living Image
Software (PerkinElmer) and reported in total flux (photon/s). To mea-
sure whole-body and liver-specific luciferase activity, identical regions
of interest (ROIs)weremeasured. These comprised either thewhole an-
imal body (excluding head and tail) or the liver, respectively (Figure S1).
Luciferase activity in the respective ROIs in each animal was measured
as described above. Off-liver luciferase activity was calculated by sub-
tracting liver-specific activity from whole-body luciferase activity.
Mouse Tissue DNA Preparation for Quantification of Vector
Copy Number
At the end of the experiment, the viral copy number of liver and
spleen tissues was determined. Genomic DNAs from tissues were iso-
lated using the Blood & Tissue DNeasy kit (QIAGEN) according to
the manufacturer’s instructions. RNAs were removed using RNase
A (Fermentas). All samples were treated with DpnI (New England
Biolabs). Total vector copy number of each sample was quantified us-
ing multiplex qPCR, as previously described.55
Histopathology
Upon tissue harvesting, liver and spleen tissues with physical
abnormalities in either size or appearance observed in six animals
from four strains (Figure S2; Table S2) were sent to the UNC Animal
Histopathology Core Facility for a histopathological examination.
To this end, tissues were fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned with a microtome, and stained
with H&E. A board-certified veterinary pathologist analyzed these
H&E-stained sections.
Statistical Analysis
All data were analyzed in the R programming environment (cran.
r-project.org). Broad-sense heritability was assessed as either theecular Therapy: Methods & Clinical Development Vol. 5 June 2017 89
Molecular Therapy: Methods & Clinical Developmentinterclass correlation or the coefficient of genetic determination.46
Briefly, each of these approaches uses the ANOVA model fit and
then assesses the relative ratios of mean square explained by strain
differences relative to the mean square error in the data. Both ap-
proaches then apply a scaling factor relative to the number of samples
(n) in each treatment class as follows:
(1) Interclass correlation: (MSstrain  MSerror)/(MSstrain + (n  1)
MSerror)
(2) Coefficient of genetic determination:
ðMSstrain MSerrorÞ=ðMSstrain + ð2n 1ÞMSerrorÞ
In order to assess the significance of strain differences on given
phenotypic traits, data were normalized and ANOVA was used to
identify significance. For the model fitting assessing vector and
strain effects driving luciferase expression, we used a partial F-test
framework.
Data Availability
All data from this study, including calculated luciferase, vector copy
number levels, and raw images for luciferase calculation, are available
upon request. The 12 collaborative cross strains used within this study
are available from the Systems Genetics Core Facility (http://csbio.
unc.edu/CCstatus/index.py?run=AvailableLines), and both genotype
files and haplotype reconstructions are available for these strains on
that site.
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